Essential Thrombocythemia (ET): Moving from Palliation to Cure

References

• Cortelazzo, S., Viero, P., Finazzi, G., D'Emilio, A., Rodeghiero, F. and Barbui, T. (1990) "Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia", J. Clin. Oncol. 8, 556–562.
   PubMed Web of Science ®Google Scholar
• Fenaux, P., Simon, M., Caulier, M.T., Lai, J.L., Goudemand, J. and Bauters, F. (1990) "Clinical course of essential thrombocythemia in 147 cases", Cancer 66, 549–556.
   PubMed Web of Science ®Google Scholar
• Bellucci, S., Janvier, M., Tobelem, G., Flandrin, G., Charpak, Y., Berger, R., et al. (1986) "Essential thrombocythemias. Clinical evolutionaly and biological data", Cancer 58, 2440–2447.
   PubMed Web of Science ®Google Scholar
• Colombi, M., Radaelli, F., Zocchi, L. and Maiolo, A.T. (1991) "Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients", Cancer 67, 2926–2930.
   PubMed Web of Science ®Google Scholar
• Chistolini, A., Mazzucconi, M.G., Ferrari, A., la Verde, G., Ferrazza, G., Dragoni, F., et al. (1990) "Essential thrombo-cythemia: a retrospective study on the clinical course of 100 patients", Haematologica 75, 537–540.
   PubMed Web of Science ®Google Scholar
• Tefferi, A., Fonseca, F., Pereira, Di. and Hoagland, H.C. (2001) "A long-term retrospective study of young women with essential thrombocythemia", Mayo Clin. Proc. 76,22–28.
   PubMed Web of Science ®Google Scholar
• Cervantes, F., Tassies, D., Salgado, C., Rovira, M., Pereira, A. and Rozman, C. (1991) "Acute transformation in nonleu-kemic chronic myeloproliferative disorders: actuarial proba-bility and main characteristics in a series of 218 patients", Acta Haematol. 85, 124–127.
   PubMed Web of Science ®Google Scholar
• Cervantes, F., Alvarez-Larran, A., Talarn, C., Gomez, M. and Montserrat, E. (2002) "Myelofibrosis with myeloid metapla-sia following essential thrombocythaemia: actuarial proba-bility, presenting characteristics and evolution in a series of 195 patients", Br. J. Haematol. 118, 786–790.
   PubMed Web of Science ®Google Scholar
• Jantunen, R., Juvonen, E., Ikkala, E., Oksanen, K., Anttila, P. and Ruutu, T. (2001) "The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia", Ann. Hematol. 80, 74–78.
   PubMed Web of Science ®Google Scholar
• Tsimberidou, A.M. and Giles, F.J. (2002) "The evolving role of ribonucleoside reductase inhibitors in hematologic malignancies", Exp. Rev. Anticancer Then 2, 437–448.
   PubMedGoogle Scholar
• Finazzi, G. and Barbui, T. (2001) "Efficacy and safety of hydroxyurea in patients with essential thrombocythemia", Pathol. Biol. (Paris) 49, 167–169.
   PubMed Web of Science ®Google Scholar
• Hoffmann, R. (2000) "Primary thrombocythemia", In: Hoffman, R., Benz, E.J., Shattil, S.J., Furie, B., Cohen, H.J., Silberstein, L.E. and McGlave, P., eds, Hematology: Basic Principles and Practice (Churchill Livingstone, Philadelphia, PA), pp. 1188–1204.
   Google Scholar
• Tefferi, A. and Murphy, S. (2001) "Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management", Blood Rev. 15, 121–131.
   PubMed Web of Science ®Google Scholar
• Cortelazzo, S., Finazzi, G., Ruggeri, M., Vestri, O., Galli, M., Rodeghiero, F., et al. (1995) "Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis", N. Engl. J. Med. 332, 1132–1136.
   PubMed Web of Science ®Google Scholar
• van den Anker-Lugtenburg, P.J. and Sizoo, W. (1990) "Myelodysplastic syndrome and secondary acute leukemia after treatment of essential thrombocythemia with hydroxy-urea", Am. J. Hematol. 33, 152.
   PubMed Web of Science ®Google Scholar
• Vinti, H., Taillan, B., Pesce, A., Michiels, J.F., Bayle, J. and Cassuto, J.P. (1990) "Megakaryoblastic transformation of essential thrombocythemia, hypercalcemia and lytic bone lesions", Acta Haematol. 83, 53.
   PubMed Web of Science ®Google Scholar
• Reiffers, J., Dachary, D., David, B., Bernard, P., Marit, G., Boisseau, M., et al. (1985) "Megakaryoblastic trans-formation of primary thrombocythemia", Acta Haematol. 73, 228–231.
   PubMed Web of Science ®Google Scholar
• Murphy, S., Peterson, P., Rand, H. and Laszlo, J. (1997) "Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment", Semin. Hematol. 34, 29–39.
   PubMed Web of Science ®Google Scholar
• Furgerson, J.L., Vukelja, S.J., Baker, W.J. and O'Rourke, T.J. (1996) "Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxy-urea", Am. J. Hematol. 51, 137–140.
   PubMed Web of Science ®Google Scholar
• Lofvenberg, E., Nordenson, I. and Wahlin, A. (1990) "Cytogenetic abnormalities and leukemic transformation in hydroxyurea-treated patients with Philadelphia chromo-some negative chronic myeloproliferative disease", Cancer Genet. Cytogenet. 49, 57–67.
   PubMed Web of Science ®Google Scholar
• Ferrari, D., Ticozzelli, G., De Vizzi, M., Corigliano, P. and De Vizzi, G. (1993) "Essential thrombocythemia and acute leukemia", Haematologica 78, 401–402.
   PubMed Web of Science ®Google Scholar
• Weinfeld, A., Swolin, B. and Westin, J. (1994) "Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications", Fur. J. Haematol. 52, 134–139.
   PubMed Web of Science ®Google Scholar
• Berkhan, L.C., Nelson, J., Ockelford, PA. and Browett, P.J. (1996) "Transformation of essential thrombocythaemia to acute lymphoblastic leukaemia", Leuk. Lymphoma 20, 347–349.
   PubMed Web of Science ®Google Scholar
• Liozon, E., Brigaudeau, C., Trimoreau, E, Desangles, F., Fermeaux, V., Praloran, V., et al. (1997) "Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukaemic transformation and review of the literature", Hematol. Cell 39, 11–18.
   PubMedGoogle Scholar
• Liozon, E. and Turlure, P. (1998) "Leukemic risk in thrombocythemia", Ann. Med. Intern. (Paris) 149, 82–86.
   PubMedGoogle Scholar
• Sterkers, Y, Preudhomme, C., Lai, J.L., Demory, J.L., Caulier, M.T., Wattel, E., et al. (1998) "Acute myeloid leukemia and myelodysplastic syndromes following essential thrombo-cythemia treated with hydroxyurea: high proportion of cases with 17p deletion", Blood 91, 616–622.
   PubMed Web of Science ®Google Scholar
• Hirose, Y, Masaki, Y. and Sugai, S. (2002) "Leukemic transformation with trisomy 8 in essential thrombocythe-mia: a report of four cases", Fur. J. Haematol. 68, 112–116.
   PubMed Web of Science ®Google Scholar
• Finazzi, G., Ruggeri, M., Rodeghiero, F. and Barbui, T. (2000) "Second malignancies in patients with essential thrombo-cythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial", Br. J. Haematol. 110, 577–583.
   PubMed Web of Science ®Google Scholar
• Silverstein, M.N., Petitt, R.M., Solberg, L.A.J., Fleming, J.S., Knight, R.C. and Schacter, L.P. (1988) "Anagrelide: a new drug for treating thrombocytosis", N. Engl. J. Med. 318, 1292–1294.
   PubMed Web of Science ®Google Scholar
• Tomer, A. (2002) "Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia", Blood 99, 1602–1609.
   PubMed Web of Science ®Google Scholar
• Solberg, L.A.J., Tefferi, A., Oles, K.J., Tarach, J.S., Petitt, R.M., Forstrom, L.A., et al. (1997) "The effects of anagrelide on human megakaryocytopoiesis", Br. J. Haematol. 99, 174–180.
   PubMed Web of Science ®Google Scholar
• Abe Andes, W., Noveck, R.J. and Fleming, J.S. (1984) "Inhibition of platelet production induced by an antiplatelet drug, anagrelide, in normal volunteers", Thromb. Haemo-stasis 52, 325–328.
   PubMed Web of Science ®Google Scholar
• Tefferi, A., Silverstein, M.N., Petitt, R.M., Mesa, R.A. and Solberg, L.A.J. (1997) "Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of action, efficacy, toxicity, current indications", Semin. Thromb. Hemost. 23, 379–383.
   PubMed Web of Science ®Google Scholar
• Spencer, C.M. and Brogden, R.N. (1994) "Anagrelide: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of thrombocythemia", Drugs 47, 809–822.
   PubMed Web of Science ®Google Scholar
• Pescatore, S.L. and Lindley, C. (2000) "Anagrelide: a novel agent for the treatment of myeloproliferative disorders", Expert Opin. Pharmacother. 1, 537–546.
   PubMedGoogle Scholar
• McCune, J.S., Liles, D. and Lindley, C. (1997) "Precipitous fall in platelet count with anagrelide: case report and critique of dosing recommendations", Pharmacotherapy 17, 822–826.
   PubMed Web of Science ®Google Scholar
• Silverstein, M.N. (1995) "Anagrelide in myeloproliferative diseases", In: Wasserman, L.R., Berk, PD. and Berlin, NJ., eds, Polycythemia Vera and the Myeloproliferative Disorders (Saunders W.B., Philadelphia), p. 329.
   Google Scholar
• Anagrelide Study Group(1992) "Anagrelide, a therapy for thrombocythemic states: experience in 577 patients", Am. J. Med. 92, 69–76.
   PubMed Web of Science ®Google Scholar
• Petrides, P.E., Beykirch, M.K. and Trapp, O.M. (1998) "Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experience in 48 patients in Germany", Fur. J. Haematol. 61, 71–76.
   PubMed Web of Science ®Google Scholar
• Wang, Q., Miyakawa, Y., Fox, N. and Kaushansky, K. (2000) "Interferon-alpha directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1", Blood 96, 2093–2099.
   PubMed Web of Science ®Google Scholar
• Ganser, A., Carlo-Stella, C., Greher, J., Volkers, B. and Hoelzer, D. (1987) "Effect of recombinant interferons alpha and gamma on human bone marrow-derived megakaryo-cytic progenitor cells", Blood 70, 1173–1179.
   PubMed Web of Science ®Google Scholar
• Tsuji, K., Muraoka, K. and Nakahata, T. (1998) "Interferon-gamma and human megakaryopoiesis", Leuk. Lymphoma 31, 107–113.
   PubMed Web of Science ®Google Scholar
• Meager, A. (1991) "Interferons alpha and beta", In: Cliffs, E., ed, Cytokines (Prentice Hall, NJ), pp. 180–195.
   Google Scholar
• Mazur, E.M., Richtsmeier, W.J. and South, K. (1986) "Alpha-interferon: differential suppression of colony growth from human erythroid, myeloid, and megakaryocytic hemato-poietic progenitor cells", J. Intetferon Res. 6, 199–206.
   PubMedGoogle Scholar
• Han, Z.C., Briere, J., Abgrall, J.F., Le Gall, G., Parent, D. and Sencebe, L. (1987) "Effects of recombinant human interferon alpha on human megakaryocyte and fibroblast colony formation", J. Biol. Regul. Homeost. Agents 1, 195–200.
   PubMedGoogle Scholar
• Gugliotta, L., Bagnara, G.P., Catani, L., Gaggioli, L., Guarini, A., Zauli, G., et al. (1989) "In vivo and in vitro inhibitory effect of alpha-interferon on megakaryocyte colony growth in essential thrombocythaemia", Br. J. Haematol. 71, 177–181.
   PubMed Web of Science ®Google Scholar
• Gilbert, H.S. (1998) "Long term treatment of myeloproli-ferative disease with interferon-alpha-2b: feasibility and efficacy", Cancer 83, 1205–1213.
   PubMed Web of Science ®Google Scholar
• Sacchi, S., Gugliotta, L., Papineschi, E, Liberati, A.M., Rupoli, S., Delfini, C., et al. (1998) "Alfa-interferon in the treatment of essential thrombocythemia: clinical results and evaluation of its biological effects on the hematopoietic neoplastic clone. Italian Cooperative Group on ET", Leukemia 12, 289–294.
   PubMed Web of Science ®Google Scholar
• Lazzarino, M., Vitale, A., Morra, E., Gagliardi, A., Bernasconi, P, Torromeo, K.C., et al. (1990) "Therapy of essential thrombocythemia with alpha-interferon: results and prospects", Fur. J. Haematol. 45, 15–21.
   PubMed Web of Science ®Google Scholar
• Sacchi, S., Tabilio, A., Leoni, P., Riccardi, A., Vecchi, A., Messora, C., et al. (1991) "Interferon alpha-2b in the long-term treatment of essential thrombocythemia", Ann. Hematol. 63, 206–209.
   PubMed Web of Science ®Google Scholar
• Giles, F.J., Gray, A.G., Brozovic, M., Grant, I.R., Machin, S.J., Richards, J.D.M., et al. (1988) "Alpha-interferon therapy for essential thrombocythaemia", Lancet 2, 70–72.
   PubMed Web of Science ®Google Scholar
• Giralt, M., Rubio, D., Cortes, MT., San Miguel, J., Steegmann, J.L., Serena, J., et al. (1991) "Alpha-interferon in the management of essential thrombodcythaemia", Fur. J. Cancer 27, S72—S74.
   Web of Science ®Google Scholar
• Gisslinger, H., Chott, A., Scheithauer, W., Gilly, B., Linkesch, W. and Ludwig, H. (1991) "Interferon in essential thrombocythaemia", Br. J. Haematol. 79, 42–47.
   PubMed Web of Science ®Google Scholar
• Kasparu, H., Bernhart, M., Krieger, O. and Lutz, D. (1992) "Remission may continue after termination of 'INF alpha-2b treatment for essential thrombocythemia", Fur. J. Haematol. 48, 33–36.
   PubMed Web of Science ®Google Scholar
• Catani, L., Gugliotta, L., Cascione, M.L., Mattioli-Belmonte, M., Vianelli, N., Belardinelli, A.R., et al. (1991) "Platelet function and interferon alpha-2a treatment in essential thrombocythaemia", Fur. J. Haematol. 46, 158–162.
   PubMed Web of Science ®Google Scholar
• Berte, R., Vallisa, D., Ferrari, B., Civardi, G., Sbolli, G. and Cavanna, L. (1996) "Low-dose interferon alpha treatment in essential thrombocythemia", Fur. J. Haematol. 56, 104–105.
   PubMed Web of Science ®Google Scholar
• Merup, M., Aberg, W., Lofvenberg, E., Svensson, E., Engman, K., Paul, C., et al. (2002) "Symptoms, symptom distress and health-related quality of life in patients with polycythaemia vera or essential thrombocythaemia during treatment with interferon-alpha", Acta Oncol. 41, 50–55.
   PubMed Web of Science ®Google Scholar
• Lengfelder, E., Griesshammer, M. and Hehlmann, R. (1996) "Interferon-alpha in the treatment of essential thrombo-cythemia", Leuk. Lymphoma 22, 135–142.
   PubMed Web of Science ®Google Scholar
• Middelhoff, G. and Boll, I. (1992) "A long-term clinical trial of interferon alpha-therapy in essential thrombocythemia", Ann. Hematol. 64, 207–209.
   PubMed Web of Science ®Google Scholar
• Sacchi, S. (1995) "The role of alpha-interferon in essential thrombocythaemia, polycythemia and myelofibrosis with myeloid metaplasia (MMM): a concise update", Leuk. Lymphoma 19, 13–20.
   PubMed Web of Science ®Google Scholar
• Akard, L.P., Hoffman, R., Elias, L. and Saiers, J.H. (1986) "Alpha-interferon and immune hemolytic anemia", Ann. Intern. Med. 105, 306.
   PubMed Web of Science ®Google Scholar
• Conlon, K.C., Urba, W.J., Smith, J.W., Steis, R.G., Longo, Di. and Clark, J.W. (1990) "Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy", Cancer 65, 2237–2242.
   PubMed Web of Science ®Google Scholar
• Wandl, U.B., Nagel-Hiemke, M., May, D., Kreuzfelder, E., Kloke, O., Kranzfhoff, M., et al. (1992) "Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders", Clin. Immunol. Immunopathol. 65, 70–74.
   PubMedGoogle Scholar
• Kurschel, E., Metz-Kurschel, U., Niederle, N. and Aulbert, E. (1991) "Investigations of the subclinical and clinical nephrotoxicity of interferon alpha-2B in patients with myeloproliferative syndromes", Renal. Fail. 13, 87–93.
   PubMed Web of Science ®Google Scholar
• Frankova, H., Gaja, A. and Hejlova, N. (2000) "Pulmonary sarcoidosis in a patient with essential thrombocythemia treated with interferon alpha: a short case report", Med. Sci. Monit. 6, 380–382.
   PubMedGoogle Scholar
• Hengstman, G.J., Vogels, O.J., ter Laak, H.J., de Witte, T. and van Engelen, B.G. (2000) "Myositis during long-term interferon-alpha treatment", Neurology 54, 2186.
   PubMed Web of Science ®Google Scholar
• Pogliani, E.M., Rossini, F., Miccolis, I., Ferrario, A., Perego, D., Casaroli, I., et al. (1995) "Alpha interferon as initial treatment of essential thrombocythemia. Analysis after two years of follow-up", Tumori 81, 245–248.
   PubMed Web of Science ®Google Scholar
• Tornebohm-Roche, E., Merup, M., Lockner, D. and Paul, C. (1995) "Alpha-2a interferon therapy and antibody formation in patients with essential thrombocythemia and polycythe-mia vera with thrombocytosis", Am. J. Hematol. 48, 163–167.
   PubMed Web of Science ®Google Scholar
• Delage, R., Demers, C., Cantin, G. and Roy, J. (1996) "Treatment of essential thrombocythemai during pregnancy with interferon-alpha", Obstet. Gynecol. 87, 814–817.
   PubMed Web of Science ®Google Scholar
• Griesshammer, M., Heimpel, H. and Pearson, T.C. (1996) "Essential thrombocythemia and pregnancy", Leuk. Lym-phoma 22, 57–63.
   PubMed Web of Science ®Google Scholar
• Inada, Y., Furukawa, M., Sasaki, H., Kodera, Y., Hiroto, M., Nishimur, H., et al. (1995) "Biomedical and biotechnological application of PEG- and PM-modified proteins", Trends Biotechnol. 13, 86–91.
   PubMed Web of Science ®Google Scholar
• Delgado, C., Sancho, P., Mendieta, J. and Luque, J. (1992) "Ligand-receptor interactions in affinity cell partitioning. Studies with transferrin covalently linked to monomethoxy-poly (ethlylene glycol) and rat reticulocytes", J. Chromatogr. 594, 97–103.
   PubMed Web of Science ®Google Scholar
• Wang, YS., Youngster, S., Bausch, J., Zhang, R., McNemar, C. and Wyss, D.F. (2000) "Identification of the major positional isomer of pegylated interferon alpha-2b", Biochemistry 39, 10634–10640.
   PubMed Web of Science ®Google Scholar
• Glue, P., Fang, J.W., Rouzier-Panis, R., Raffanel, C., Sabo, R., Gupta, S.K., et al. (2000) "Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and prelimi-nary efficacy data. Hepatitis C Intervention Therapy Group", Clin. Pharmacol. Then 68, 556–567.
   PubMed Web of Science ®Google Scholar
• Reddi, K.R., Wright, T.L., Pockros, P.J., Shiffman, M., Everson, G., Reindollar, R., et al. (2001) "Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C", Hepatology 33, 433–438.
   PubMed Web of Science ®Google Scholar
• Tobelem, G. (1989) "Essential thrombocythaemia", Bailliere's Clin. Haematol. 2, 719–728.
   PubMedGoogle Scholar
• Geller, S.A. and Shapiro, E. (1982) "Acute leukemia as a natural sequel to primary thrombocythemia", Am. J. Clin. Pathol. 77, 353–356.
   PubMed Web of Science ®Google Scholar
• Barbui, T., Finazzi, G., Dupuy, E., Kiladjian, J.J. and Briere, J. (1996) "Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers", Leuk. Lymphoma 22\(Suppl. 1), 149–160.
   PubMed Web of Science ®Google Scholar
• Solberg, A.L. (2002) "Therapeutic options for essential thrombocythemia and polycythemia vera", Semin. Oncol. 29, 10–15.
   PubMed Web of Science ®Google Scholar
• Randi, M.L., Fabris, F. and Girolami, A. (2000) "Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia", Leuk. Lymphoma 37, 379–385.
   PubMed Web of Science ®Google Scholar
• Berrebi, A., Shvidel, L., Shtalrid, M. and Klepfish, A. (2000) "Short course of busulphan in essential thrombo-cythaemia: remodelling af an old strategy", Br. J. Haematol. 109, 249–250.
   PubMed Web of Science ®Google Scholar
• de Pauw, B.E., van Bergen, A.N., Haanen, C. and Steenbergen, J. (1985) "Intermittent melphalan in the treatment of essential thrombocytosis with haemorrhage or thrombosis", Scand. J. Haematol. 35, 448–450.
   PubMedGoogle Scholar
• Kwong, Y.L., Liang, R.H., Chiu, E.K., Lie, A.K., Chan, L.C., Todd, D., et al. (1995) "Essential thrombocythemia: a retrospective analysis of 39 cases", Am. J. Hematol. 49, 39–42.
   PubMed Web of Science ®Google Scholar
• Murphy, S., Rosenthal, D.S., Weinfeld, A., Briere, J., Faguet, G.B., Knospe, W.H., et al. (1982) "Essential thrombocythe-mia: response during first year of therapy with melphalan and radioactive phosphorus: a polycythemia Vera Study Group report", Cancer Treat. Rep. 66, 1495–1500.
   PubMedGoogle Scholar
• Gris, J.C., Schved, J.F., Arnaud, A. and Chauvet, C. (1989) "Myelodysplastic syndrome and secondary acute leukemia after treatment of essential thrombocythemia with melpha-lan", Am. J. Hematol. 30, 47–48.
   PubMed Web of Science ®Google Scholar
• Berlin, N.I. (2000) "Treatment of the myeloproliferative disorders with 32P", Fur. J. Haematol. 65, 1–7.
   PubMed Web of Science ®Google Scholar
• Passamonti, F., Malabarba, L., Orlandi, E., Pascutto, C., Brusamolino, E., Astori, C., et al. (2002) "Pipobroman is safe and effective treatment for patients with essential thrombo-cythaemia at high risk of thrombosis", Br. J. Haematol. 116, 855–861.
   PubMed Web of Science ®Google Scholar
• Messora, C., Bensi, L., Vanzanelli, P., Temperani, P., Carotenuto, M. and Sacchi, S. (1996) "Myelodysplastic transformation in a case of essential thrombocythemia treated with pipobroman", Haematologica 81, 288–289.
   PubMed Web of Science ®Google Scholar
• Merlat, A., Lai, J.L., Sterkers, Y, Demory, J.L., Bauters, F., Preudhomme, C., et al. (1999) "Therapy-related myelodys-plastic syndrome and acute myeloid leukemia with 17p deletion. A report of 25 cases", Leukemia 13, 250–257.
   PubMed Web of Science ®Google Scholar
• Randi, M.L., Fabris, F. and Girolami, A. (1999) "Leukemia and myelodysplasia in patients with essential thrombo-cythemia treated with cytotoxic agents", Haematologica 84, 1049–1050.
   PubMed Web of Science ®Google Scholar
• Sedlacek, S.M., Curtis, J.L., Weintraub, J. and Levin, J. (1986) "Essential thrombocythemia and leukemic transformation", Medicine (Bartimore) 65, 353–364.
   PubMed Web of Science ®Google Scholar
• Brandt, L. and Anderson, H. (1995) "Survival and risk of leukaemia in polycythaemia vera and essential thrombo-cythaemia treated with oral radiophosphorus: are safer drugs available?", Fur. J. Haematol. 54, 21–26.
   PubMed Web of Science ®Google Scholar
• Jurado, M., Deeg, H., Gooley, T., Anasetti, C., Chauncey, T., Flowers, M., et al. (2001) "Haemopoietic stem cell transplantation for advanced polycythaemia or essential thrombocythaemia", Br. J. Haematol. 112, 392–396.
   PubMed Web of Science ®Google Scholar
• Anderson, J.E., Sale, G., Appelbaum, ER., Chauncey, T.R. and Storb, R. (1997) "Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis", Br. J. Haematol. 98, 1010–1016.
   PubMed Web of Science ®Google Scholar
• Xu, X.M., Sansores-Garcia, L., Chen, X.M., Matijevic-Aleksic, N., Du, M. and Wu, K.K. (1999) "Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate", Proc. Natl Acad. Sci. USA 96, 5292–5297.
   PubMed Web of Science ®Google Scholar
• Griesshammer, M., Bargerter, M., van Vliet, H.H. and Michiels, J.J. (1997) "Aspirin in essential thrombocythemia: status quo and quo vadis", Semin. Thromb. Hemost. 23, 371–377.
   PubMed Web of Science ®Google Scholar
• van Genderen, P.J., Prins, F.J., Michiels, J.J. and Schror, K. (1999) "Thromboxane-dependent platelet activation in vivo precedes arterial thrombosis in thrombocythaemia: a rationale for the use of low-dose aspirin as an antithrombotic agent", Br. J. Haematol. 104, 438–441.
   PubMed Web of Science ®Google Scholar
• Vantroyen, B. and Vanstraelen, D. (2002) "Management of essential thrombocythemia during pregnancy with aspirin, interferon alpha-2a and no treatment. A comparative analysis of the literature", Acta Haematol. 107, 158–169.
   PubMed Web of Science ®Google Scholar
• Beressi, A.H., Tefferi, A., Silverstein, MN., Petitt, R.M. and Hoagland, H.C. (1995) "Outcome analysis of 34 pregnancies in women with essential thrombocythemia", Arch. Intern. Med. 155, 1217–1222.
   PubMed Web of Science ®Google Scholar
• Wright, C.A. and Tefferi, A. (2001) "A single institutional experience with 43 pregnancies in essential thrombocythe-mia", Fur. J. Haematol. 66, 152–159.
   PubMed Web of Science ®Google Scholar
• Van de Pette, J.E., Prochazka, A.V., Pearson, T.C., Singh, A.K., Dickson, E.R. and Wetherley-Mein, G. (1986) "Primary thrombocythaemia treated with busulphan", Br. J. Haematol. 62, 229–237.
   PubMed Web of Science ®Google Scholar
• Ross, R., Raines, E. and Bowen-Pope, D. (1982) "Growth factors from platelets, monocytes, and endothelium: their role in cell proliferation", Ann. N.Y. Acad. Sci. 397, 18–24.
   PubMed Web of Science ®Google Scholar
• Sosman, J.A., Verma, A., Moss, S., Sorokin, P., Blend, M., Bradlow, B., et al. (2000) "Interleukin 10-induced thrombo-cytopenia in normal healthy adult volunteers: evidence for decreased platelet production", Br. J. Haematol. 111, 104–111.
   PubMed Web of Science ®Google Scholar
• Gersuk, G.M., Carmel, R. and Pattengale, P.K. (1989) "Platelet-derived growth factor concentrations in platelet-poor plasma and urine from patients with myeloprolifera-five disorders", Blood 74, 2330–2334.
   PubMed Web of Science ®Google Scholar
• Lev, P.R., Marta, R.F., Vassallu, P. and Molinas, F.C. (2002) "Variation of PDGF, TGFbeta, and bFGF levels in essential thrombocythemia patients treated with anagrelide", Am. J. Hematol. 70, 85–91.
   PubMed Web of Science ®Google Scholar
• Zauli, G., Visani, G., Catani, L., Vianelli, N., Gugliotta, L. and Capitani, S. (1993) "Reduced responsiveness of bone marrow megakaryocyte progenitors to platelet-derived transforming growth factor beta 1, produced in normal amount in patients with essential thrombocythaemia", Br. J. Haematol. 83, 14–20.
   PubMed Web of Science ®Google Scholar
• Wehmeier, A. and Sudhoff, T. (1997) "Elevated plasma levels of basic fibroblast growth factor in patients with essential thrombocythemia and polycythemia vera", Br. J. Haematol. 98, 1050–1051.
   PubMed Web of Science ®Google Scholar